Asked by: Lorraine Beavers (Labour - Blackpool North and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of a cross-government alcohol strategy.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government recognises that alcohol-related harm has wide ranging impacts across health, crime, productivity, and communities.
Commitments to addressing harms from alcohol feature in several of the Government's current strategies and plans. The National Health Service 10-Year Health Plan outlines crucial steps to help people make healthier choices about alcohol, including making it a legal requirement for alcohol labels to display health warnings and consistent nutritional information. This was reemphasised in the National Cancer Plan. The Men’s Health Strategy outlines the impact alcohol can have on men’s health, and announced the pilot of a new brief intervention to target the rise in cardiovascular disease deaths from combined alcohol and cocaine use among older men. To support better outcomes for people experiencing harmful drinking, the first ever United Kingdom clinical guidelines on alcohol treatment were published in November 2025.
The Government keeps the evidence on alcohol-related harm and the effectiveness of different policy approaches under review, and continues to consider how cross-Government action can best support improvements in population health and reduce health inequalities.
Asked by: Lorraine Beavers (Labour - Blackpool North and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the decision to cease updates to fatty liver disease data on Office for Health Improvement and Disparities Fingertips profiles on trends in the level of those diseases.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
The Office for Health Improvement and Disparities (OHID) ceased to update non-alcoholic fatty liver disease (NAFLD) hospital admissions rates and premature deaths, in people aged under 75 years old, on the Fingertips profiles in December 2025. These only measure the most serious, and a small proportion of cases of the disease, and did not relate directly to the disease prevalence, level of disease, within the population.
These are not accurate measures of NAFLD within the population, a condition that is linked to obesity and which can be prevented and treated at early stages with healthy lifestyle changes. The latest reported data for England showed that 345 deaths due to NAFLD in 2023 and 3,126 hospital admissions in 2022/23. There is no data measuring the prevalence of NAFLD.
The decision to cease updates occurred after a process that examined data usage, potential duplication, and relative impact of the indicator on disease prevention and monitoring.
We concluded that the cessation of publication of these indicators would have limited impact on our efforts to monitor trends on the level of these diseases within the population.
Alternative data sources to monitor the population risk of this condition include measures of obesity, physical activity, and nutrition which continue to be published by OHID.
Asked by: Lorraine Beavers (Labour - Blackpool North and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps NHS England is taking, working with manufacturers of breakthrough treatments for fatty liver disease, to prepare the NHS to deliver such treatments as quickly as possible to eligible patients once approved.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Newly licensed medicines are appraised by the National Institute for Health and Care Excellence (NICE), which is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE aims wherever possible to issue draft guidance on new medicines close to the time of licensing. The NHS in England is legally required to fund drugs recommended by NICE, usually within three months of final guidance.
NICE is currently evaluating potential new treatments for metabolic dysfunction-associated steatohepatitis (MASH) in anticipation of the medicines being granted a marketing authorisation by the Medicines and Healthcare products Regulatory Agency with guidance expected later this year. NHS England is actively preparing to support the potential introduction of new treatments for MASH, including fatty liver disease with fibrosis, alongside the ongoing NICE appraisal process.
The Department and NHS England will continue to work to ensure that, once approved, effective new treatments for fatty liver disease are introduced in a way that is fair, affordable, and which protects the wider NHS, while ensuring that patients with the greatest clinical need are able to benefit as quickly as possible.
Asked by: Lorraine Beavers (Labour - Blackpool North and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 12 February to Question 110590 on Breast Cancer: Screening, whether the National Inherited Cancer Predisposition Registry will include women assessed as being at moderate or high risk of breast cancer who do not have an identified genetic mutation.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The National Inherited Cancer Predisposition Registry already includes some women who do not have an identified genetic mutation. National cancer registration data collects high-quality data in the National Inherited Cancer Predisposition Registry on women at very high risk of breast cancer according to The Surveillance of women at very high risk of developing breast cancer guidelines, which are available at the following link:
As well as women at high risk of breast cancer who have an identified genetic mutation, the registry collects data on ‘risk-equivalent’ women who have a strong family history of breast cancer, but who have not undertaken a definitive genetic test and therefore do not have an identified genetic mutation. Their eligibility criteria can be found at the following link:
Women from the breast cancer after radiotherapy dataset, or BARD, are also included. These women have received radiotherapy to the chest area involving breast tissue for the treatment of lymphoma between the ages of 10 and 35 years old. They are identified by linking national cancer registration data to the national Radiotherapy Dataset within National Disease Registration Service, as both are nationally mandated datasets.
Asked by: Lorraine Beavers (Labour - Blackpool North and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of integrating all at risk screening for breast cancer into the National NHS Breast Screening Programme.
Answered by Ashley Dalton
The new and world-leading NHS National Inherited Cancer Predisposition Registry (NICPR), part of the National Disease Registration Service, will help the National Health Service to deliver proactive, targeted prevention, surveillance, and earlier diagnosis for people and their families. Women at Very High Risk (VHR) of breast cancer are now identified within the NICPR and referred into the NHS Breast Screening Programme (NHSBSP), which has enabled reconciliation to ensure that all identified women are safely referred into the programme. This is a step towards a fully electronic referral VHR process into the NHSBSP.
The Government is advised on all screening matters by the UK National Screening Committee (UK NSC), an independent scientific advisory committee which is made up of leading medical and screening experts. Where the UK NSC is confident that offering screening provides more good than harm, they recommend a screening programme.
In 2022 the remit of the UK NSC was expanded to include targeted, and risk stratified screening, in addition to population screening. So far, the UK NSC has not made a recommendation for targeted screening of women at a moderate or high risk of breast cancer.
Currently, if women reach the criteria for moderate or high- risk screening with surveillance recommended, this is offered as part of screening provision managed locally with NHS trusts.
Asked by: Lorraine Beavers (Labour - Blackpool North and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the extent of regional inequities in the provision of early access programmes for (a) innovative treatments and (b) people living with SOD1 motor neurone disease.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Company-led early access programmes (EAPs) are not endorsed by the Department or NHS England and no assessment has been made of whether there are regional inequities in the provision of early access programmes for innovative treatments and people living with SOD1 motor neurone disease.
Participation in company-led schemes is decided at an individual NHS trust level. Under these programmes, the cost of the drug is free to both patients taking part in it, and to the National Health Service, but NHS trusts must still cover administration costs and provide clinical resources to deliver the EAP.
NHS England has published guidance for integrated care systems (ICS) on free of charge medicines schemes, providing advice on potential financial, resourcing, and clinical risks. ICSs should use the guidance to help determine whether to implement any free of charge scheme including assessing suitability and any risks in the short, medium, and long term. The guidance is available at the following link: